Pfizer will begin human trials of an omicron-specific COVID-19 vaccine beginning in late January, a company spokesperson confirmed Monday to FOX TV Stations. "We already have begun work on a DNA ...

The adjusted VE against infection of any severity was 58.8% for BNT162b2 and 73.9% for mRNA-1273. Both vaccines maintained high protection in children with underlying medical conditions and reduced ...

Pfizer and BioNTech have begun a clinical trial for their Omicron-specific COVID-19 vaccine candidate, they announced in a news release on Tuesday. The study will evaluate the vaccine for safety, ...

Pfizer and BioNTech said Wednesday that initial lab tests show that the omicron variant partly escapes protection offered by the companies' two-dose regimen of their COVID-19 vaccine. However, those ...

Pfizer and BioNTech released more human data Friday indicating the omicron BA.5 boosters perform better than the old Covid shots. Stream NBC 5 for free, 24/7, wherever you are. People older than 55 ...

In "sobering news," omicron can evade the protection initial vaccines give, but boosters increase efficacy and better protect against the newest variant of concern, Dr. Anthony Fauci said Sunday. The ...

Pfizer and BioNTech said Tuesday they've begun clinical trials for an omicron-based COVID-19 vaccine. According to a press release, the vaccine will be tested initially in adults aged 18 to 55. "While ...